When Judge Rodgers confirmed that Pfizer and plaintiffs’ leadership had reached a global settlement in principle, thousands of women asked
Two facts anchor a Depo-Provera claim: a meningioma diagnosis, which is usually well documented, and a history of DMPA use,
As of December 2025, the Depo-Provera label warns that prolonged use may increase the risk of intracranial meningioma and recommends
On June 15, 2026, the judge overseeing the Depo-Provera MDL confirmed that Pfizer and plaintiffs’ leadership had reached a global
Depo-Provera is depot medroxyprogesterone acetate (DMPA), a progestin injected every three months for contraception. Pfizer holds the brand. The litigation
Depo-Provera was the convenient choice. Four injections a year, no daily pill, no device. For decades it was recommended to
Women are suing over Depo Provera, claiming long-term use caused brain tumors like meningiomas. If you developed neurological symptoms, you
In 2025, Depo Provera lawsuits entered a new phase as regulators, medical researchers, and women’s health advocates pushed for deeper
Depo-Provera lawsuits in 2025 are helping women diagnosed with meningioma brain tumors seek justice. Learn your legal options and how
Request a free case review. It takes about two minutes and there is no obligation.
